These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O Front Immunol; 2020; 11():1704. PubMed ID: 32849600 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a. Kim TK; Park CS; Jang J; Kim MR; Na HJ; Lee K; Kim HJ; Heo K; Yoo BC; Kim YM; Lee JW; Kim SJ; Kim ES; Kim DY; Cha K; Lee TG; Lee S Mol Oncol; 2018 Mar; 12(3):356-372. PubMed ID: 29316206 [TBL] [Abstract][Full Text] [Related]
4. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682 [TBL] [Abstract][Full Text] [Related]
5. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824 [TBL] [Abstract][Full Text] [Related]
6. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670 [TBL] [Abstract][Full Text] [Related]
7. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. Ruixin S; Yifan L; Yansha S; Min Z; Yiwei D; Xiaoli H; Bizhi S; Hua J; Zonghai L Br J Pharmacol; 2024 Nov; 181(22):4628-4646. PubMed ID: 39129178 [TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
9. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Mura M; Swain RK; Zhuang X; Vorschmitt H; Reynolds G; Durant S; Beesley JF; Herbert JM; Sheldon H; Andre M; Sanderson S; Glen K; Luu NT; McGettrick HM; Antczak P; Falciani F; Nash GB; Nagy ZS; Bicknell R Oncogene; 2012 Jan; 31(3):293-305. PubMed ID: 21706054 [TBL] [Abstract][Full Text] [Related]
10. Effective Targeting of TAG72 Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ Front Immunol; 2018; 9():2268. PubMed ID: 30510550 [TBL] [Abstract][Full Text] [Related]
11. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. Petrovic K; Robinson J; Whitworth K; Jinks E; Shaaban A; Lee SP PLoS One; 2019; 14(10):e0224015. PubMed ID: 31622431 [TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Qu J; Mei Q; Chen L; Zhou J Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047 [TBL] [Abstract][Full Text] [Related]
14. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Ki MK; Jeoung MH; Choi JR; Rho SS; Kwon YG; Shim H; Chung J; Hong HJ; Song BD; Lee S Oncogene; 2013 Nov; 32(48):5449-57. PubMed ID: 23644659 [TBL] [Abstract][Full Text] [Related]
15. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. Robinson J; Whitworth K; Jinks E; Nagy Z; Bicknell R; Lee SP J Pathol Clin Res; 2020 Oct; 6(4):308-319. PubMed ID: 32696621 [TBL] [Abstract][Full Text] [Related]
17. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295 [TBL] [Abstract][Full Text] [Related]
18. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775 [TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice. Jindal V; Arora E; Masab M; Gupta S Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]